Delafloxacin Approved for Treatment of Skin Infections

FDA approval gives us another option that should not be overused.

On June 19, 2017, the FDA announced approval of delafloxacin (Baxdela) for treatment of acute bacterial skin and skin-structure infections (ABSSSIs) caused by various gram-positive and gram-negative pathogens, including Staphylococcus aureus (methicillin-resistant [MRSA] and methicillin-susceptible [MSSA] strains), S. haemolyticus, S. lugdunensis, Streptococcus pyogenes, S. agalactiae, S. anginosus group, Enterococcus faecalis, Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, and Pseudomonas aeruginosa.

In two phase III, randomized, double-blind, multicenter trials totaling 1510 patients treated for 5 to 14 days, delafloxacin was noninferior to vancomycin 15 mg/kg plus aztreonam. Recommended doses of delafloxacin are 300 mg (20…

Author

George Sakoulas, MD

Disclosures

Consultant/Advisory BoardParatek Pharmaceuticals; Nestle Corp.; AbbVie; Shionogi

Speaker’s BureauAllergan/AbbVie; Paratek Pharmaceuticals; Nestle Corp.

RoyaltiesUpToDate

Editorial BoardsAntimicrobial Agents and Chemotherapy; Open Forum Infectious Diseases